Douglas Corley to Colorectal Neoplasms
This is a "connection" page, showing publications Douglas Corley has written about Colorectal Neoplasms.
Connection Strength
18.369
-
Surveillance Colonoscopy Findings in Older Adults With a History of Colorectal Adenomas. JAMA Netw Open. 2024 Apr 01; 7(4):e244611.
Score: 0.601
-
Colorectal Cancer Screening After Sequential Outreach Components in a Demographically Diverse Cohort. JAMA Netw Open. 2024 Apr 01; 7(4):e245295.
Score: 0.601
-
Evaluating Different Approaches for Calculating Adenoma Detection Rate: Is Screening Colonoscopy the Gold Standard? Gastroenterology. 2023 09; 165(3):784-787.e4.
Score: 0.567
-
Physician Adenoma Detection Rates and Colorectal Cancer-Reply. JAMA. 2022 10 11; 328(14):1462-1463.
Score: 0.543
-
Developing Meaningful Health Care Quality Metrics: An Example From Colonoscopy and Adenoma Detection. Ann Intern Med. 2022 10; 175(10):1479-1480.
Score: 0.541
-
Association of Physician Adenoma Detection Rates With Postcolonoscopy Colorectal Cancer. JAMA. 2022 06 07; 327(21):2114-2122.
Score: 0.530
-
Rising Early-onset Colorectal Cancer Incidence Is Not an Artifact of Increased Screening Colonoscopy Use in a Large, Diverse Healthcare System. Gastroenterology. 2022 01; 162(1):325-327.e3.
Score: 0.504
-
Early Screening of African Americans (45-50 Years Old) in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program. Gastroenterology. 2020 11; 159(5):1695-1704.e1.
Score: 0.465
-
Proton Pump Inhibitor Use and Risk of Gastric, Colorectal, Liver, and Pancreatic Cancers in a Community-Based Population. Am J Gastroenterol. 2020 05; 115(5):706-715.
Score: 0.458
-
Validation of an Algorithm to Identify Patients at Risk for Colorectal Cancer Based on Laboratory Test and Demographic Data in Diverse, Community-Based Population. Clin Gastroenterol Hepatol. 2020 11; 18(12):2734-2741.e6.
Score: 0.458
-
Natural Language Processing for the Accurate Identification of Colorectal Cancer Mismatch Repair Status in Lynch Syndrome Screening. Clin Gastroenterol Hepatol. 2021 03; 19(3):610-612.e1.
Score: 0.451
-
Long-term Risk of Colorectal Cancer and Related Death After Adenoma Removal in a Large, Community-based Population. Gastroenterology. 2020 03; 158(4):884-894.e5.
Score: 0.440
-
Effect of Sex, Age, and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and Meta-analysis. Gastroenterology. 2019 12; 157(6):1494-1505.
Score: 0.437
-
Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection. Ann Intern Med. 2019 05 21; 170(10):736-737.
Score: 0.429
-
Modifiable Failures in the Colorectal Cancer Screening Process and Their Association With Risk of Death. Gastroenterology. 2019 01; 156(1):63-74.e6.
Score: 0.410
-
When Should Guidelines Change? A Clarion Call for Evidence Regarding the Benefits and Risks of Screening for Colorectal Cancer at Earlier Ages. Gastroenterology. 2018 10; 155(4):947-949.
Score: 0.408
-
Index colonoscopy-related risk factors for postcolonoscopy colorectal cancers. Gastrointest Endosc. 2019 01; 89(1):168-176.e3.
Score: 0.407
-
Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests: A Systematic Review. Ann Intern Med. 2017 Oct 17; 167(8):565-575.
Score: 0.384
-
Primary care visit use after positive fecal immunochemical test for colorectal cancer screening. Cancer. 2017 Oct 01; 123(19):3744-3753.
Score: 0.375
-
Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis. JAMA. 2017 Apr 25; 317(16):1631-1641.
Score: 0.372
-
Optimizing patient-reported outcome and risk factor reporting from cancer survivors: a randomized trial of four different survey methods among colorectal cancer survivors. J Cancer Surviv. 2017 Jun; 11(3):393-400.
Score: 0.364
-
Endoscopist fatigue estimates and colonoscopic adenoma detection in a large community-based setting. Gastrointest Endosc. 2017 Mar; 85(3):601-610.e2.
Score: 0.357
-
Reducing Variation in the "Standard of Care" for Cancer Screening: Recommendations From the PROSPR Consortium. JAMA. 2016 May 17; 315(19):2067-8.
Score: 0.348
-
What makes a "good" colonoscopy quality indicator? Gastrointest Endosc. 2016 Jan; 83(1):179-81.
Score: 0.339
-
Factors influencing variation in physician adenoma detection rates: a theory-based approach for performance improvement. Gastrointest Endosc. 2016 Mar; 83(3):617-26.e2.
Score: 0.332
-
Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014 07 10; 371(2):186.
Score: 0.306
-
Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014 06 26; 370(26):2541.
Score: 0.305
-
Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014 Apr 03; 370(14):1298-306.
Score: 0.301
-
Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014 Feb 04; 160(3):171.
Score: 0.297
-
Colorectal-cancer screening--coming of age. N Engl J Med. 2013 Sep 19; 369(12):1164-6.
Score: 0.290
-
The road ahead: what if gastroenterologists were accountable for preventing colorectal cancer? Clin Gastroenterol Hepatol. 2013 Mar; 11(3):204-7.
Score: 0.279
-
Variation of adenoma prevalence by age, sex, race, and colon location in a large population: implications for screening and quality programs. Clin Gastroenterol Hepatol. 2013 Feb; 11(2):172-80.
Score: 0.270
-
Can we improve adenoma detection rates? A systematic review of intervention studies. Gastrointest Endosc. 2011 Sep; 74(3):656-65.
Score: 0.249
-
Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening. J Natl Cancer Inst. 2015 Jun; 107(6):djv120.
Score: 0.162
-
Fecal Immunochemical Test Screening and Risk of Colorectal Cancer Death. JAMA Netw Open. 2024 Jul 01; 7(7):e2423671.
Score: 0.153
-
Population-level impact of the BMJ Rapid Recommendation for colorectal cancer screening: a microsimulation analysis. BMJ Open Gastroenterol. 2024 May 09; 11(1).
Score: 0.151
-
Combining Asian and European genome-wide association studies of colorectal cancer improves risk prediction across racial and ethnic populations. Nat Commun. 2023 10 02; 14(1):6147.
Score: 0.145
-
Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning Ten Years after a Negative Colonoscopy, among Screen-Eligible Adults 76 to 85 Years Old. Cancer Epidemiol Biomarkers Prev. 2023 01 09; 32(1):37-45.
Score: 0.138
-
Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries. Nat Genet. 2023 01; 55(1):89-99.
Score: 0.137
-
Evaluation of Harms Reporting in U.S. Cancer Screening Guidelines. Ann Intern Med. 2022 11; 175(11):1582-1590.
Score: 0.135
-
Evaluating and Improving Cancer Screening Process Quality in a Multilevel Context: The PROSPR II Consortium Design and Research Agenda. Cancer Epidemiol Biomarkers Prev. 2022 08 02; 31(8):1521-1531.
Score: 0.134
-
Association between Improved Colorectal Screening and Racial Disparities. N Engl J Med. 2022 02 24; 386(8):796-798.
Score: 0.130
-
Response to Li and Hopper. Am J Hum Genet. 2021 03 04; 108(3):527-529.
Score: 0.121
-
Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. Am J Hum Genet. 2020 09 03; 107(3):432-444.
Score: 0.117
-
The effect of using fecal testing after a negative sigmoidoscopy on the risk of death from colorectal cancer. J Med Screen. 2021 06; 28(2):140-147.
Score: 0.115
-
A population-based survey to assess the association between cannabis and quality of life among colorectal cancer survivors. BMC Cancer. 2020 May 03; 20(1):373.
Score: 0.115
-
Increased Risk of Colorectal Cancer in Individuals With a History of Serrated Polyps. Gastroenterology. 2020 08; 159(2):502-511.e2.
Score: 0.114
-
Evaluating Screening Participation, Follow-up, and Outcomes for Breast, Cervical, and Colorectal Cancer in the PROSPR Consortium. J Natl Cancer Inst. 2020 03 01; 112(3):238-246.
Score: 0.113
-
Cumulative Burden of Colorectal Cancer-Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. Gastroenterology. 2020 04; 158(5):1274-1286.e12.
Score: 0.112
-
Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. BMJ. 2019 Oct 02; 367:l5515.
Score: 0.110
-
Colorectal Cancer Screening in People With and Without HIV in an Integrated Health Care Setting. . 2019 07 01; 81(3):284-291.
Score: 0.108
-
Treatment patterns and survival differ between early-onset and late-onset colorectal cancer patients: the patient outcomes to advance learning network. Cancer Causes Control. 2019 Jul; 30(7):747-755.
Score: 0.107
-
Overdiagnosis in Colorectal Cancer Screening: Time to Acknowledge a Blind Spot. Gastroenterology. 2018 Sep; 155(3):592-595.
Score: 0.101
-
Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population. Gastroenterology. 2018 11; 155(5):1383-1391.e5.
Score: 0.101
-
World Endoscopy Organization Consensus Statements on Post-Colonoscopy and Post-Imaging Colorectal Cancer. Gastroenterology. 2018 09; 155(3):909-925.e3.
Score: 0.101
-
Health care improvement and survivorship priorities of colorectal cancer survivors: findings from the PORTAL colorectal cancer cohort survey. Support Care Cancer. 2019 Jan; 27(1):147-156.
Score: 0.100
-
Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev. 2018 02; 27(2):158-164.
Score: 0.097
-
Impact of adenoma detection on the benefit of faecal testing vs. colonoscopy for colorectal cancer. Int J Cancer. 2017 12 01; 141(11):2359-2367.
Score: 0.095
-
Time to Diagnostic Testing After a Positive Colorectal Cancer Screening Test. JAMA. 2017 08 01; 318(5):483.
Score: 0.095
-
Colorectal Cancer Screening Initiation After Age 50 Years in an Organized Program. Am J Prev Med. 2017 Sep; 53(3):335-344.
Score: 0.093
-
Oral bisphosphonates and colorectal cancer. Sci Rep. 2017 03 10; 7:44177.
Score: 0.092
-
Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue. Dig Dis Sci. 2017 03; 62(3):678-688.
Score: 0.091
-
Fecal Immunochemical Test (FIT) for Colon Cancer Screening: Variable Performance with Ambient Temperature. J Am Board Fam Med. 2016 11 12; 29(6):672-681.
Score: 0.090
-
Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System. J Gen Intern Med. 2016 11; 31(11):1323-1330.
Score: 0.088
-
Influence of Age and Comorbidity on Colorectal Cancer Screening in the Elderly. Am J Prev Med. 2016 09; 51(3):e67-75.
Score: 0.088
-
Association Between Primary Care Visits and Colorectal Cancer Screening Outcomes in the Era of Population Health Outreach. J Gen Intern Med. 2016 10; 31(10):1190-7.
Score: 0.087
-
Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test. Clin Gastroenterol Hepatol. 2016 10; 14(10):1445-1451.e8.
Score: 0.087
-
Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity. Am J Prev Med. 2016 10; 51(4):507-12.
Score: 0.087
-
Variation in Screening Abnormality Rates and Follow-Up of Breast, Cervical and Colorectal Cancer Screening within the PROSPR Consortium. J Gen Intern Med. 2016 Apr; 31(4):372-9.
Score: 0.086
-
Racial/Ethnic Disparities in Colorectal Cancer Screening Across Healthcare Systems. Am J Prev Med. 2016 10; 51(4):e107-15.
Score: 0.086
-
Colorectal Cancer Health Disparities and the Role of US Law and Health Policy. Gastroenterology. 2016 05; 150(5):1052-1055.
Score: 0.086
-
Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study. Ann Intern Med. 2016 Apr 05; 164(7):456-63.
Score: 0.085
-
Metformin use and risk of colorectal adenoma after polypectomy in patients with type 2 diabetes mellitus. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1692-8.
Score: 0.083
-
Observational methods to assess the effectiveness of screening colonoscopy in reducing right colon cancer mortality risk: SCOLAR. J Comp Eff Res. 2015 Nov; 4(6):541-51.
Score: 0.082
-
Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening: A Microsimulation Model. JAMA. 2015 Jun 16; 313(23):2349-58.
Score: 0.082
-
Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. Cancer. 2015 Jul 01; 121(13):2281-5.
Score: 0.080
-
Colorectal cancer deaths attributable to nonuse of screening in the United States. Ann Epidemiol. 2015 Mar; 25(3):208-213.e1.
Score: 0.079
-
The colorectal cancer screening process in community settings: a conceptual model for the population-based research optimizing screening through personalized regimens consortium. Cancer Epidemiol Biomarkers Prev. 2014 Jul; 23(7):1147-58.
Score: 0.076
-
Approaches for classifying the indications for colonoscopy using detailed clinical data. BMC Cancer. 2014 Feb 15; 14:95.
Score: 0.074
-
Uncontrolled confounding in studies of screening effectiveness: an example of colonoscopy. J Med Screen. 2013 Dec; 20(4):198-207.
Score: 0.073
-
Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med. 2013 Mar 05; 158(5 Pt 1):312-20.
Score: 0.070